Related Experiment Video
Updated: Jan 13, 2026

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
Published on: February 28, 2019
MHC-II vaccine ignites cold tumors while lighting up TIGIT as a compensatory brake
Haopeng Wang1, Siyu Ji2, Chenqi Xu3
1Changping Laboratory, Beijing 102206, China; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Abstract:
Song et al. systematically characterize how an MHC-II-restricted neoantigen vaccine remodels the cold tumor microenvironment. The vaccine promotes T cell infiltration and effector function while upregulating the PVR-TIGIT checkpoint axis. Combining vaccination with TIGIT blockade achieves synergistic anti-tumor efficacy by enhancing antigen-specific CD4 T cell function and delaying exhaustion, providing a promising strategy to overcome immunotherapy resistance in cold tumors.
Related Concept Videos
Tumor Immunotherapy
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...

